Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...